Drug intelligence / Profile preview

Shigella sonnei O-SP-core conjugate vaccine

Development stage: Phase 1
Lead developer: National Institute of Child Health and Human Development
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

The Shigella sonnei O-SP-core conjugate vaccine (O-SPC-rDT) is an investigational glycoconjugate vaccine developed by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) for the prevention of shigellosis. The vaccine consists of a fragment of the *Shigella sonnei* lipopolysaccharide (LPS), comprising the O-specific polysaccharide (O-SP) and the core region (O-SPC), which is covalently bound to a recombinant non-toxic diphtheria toxin mutant (rDT) carrier protein. The saccharide component is designed with a low molecular mass, averaging 3.5 repeat units, and is coupled via its reducing end to enhance immunogenicity compared to previous full-length O-SP conjugates. The vaccine's mechanism of action involves eliciting type-specific serum IgG antibodies against the O-SP domain, an essential virulence factor and protective antigen of *S. sonnei*. It is currently being evaluated in Phase 1 clinical trials to assess safety and immunogenicity in healthy adults, with the ultimate goal of providing protection to young children, the population most affected by shigellosis.

Brand names: Shigella sonnei O-SPC/rBRU
Other names: Shigella sonnei OSPC-rDT Conjugate VaccineS. sonnei O-SP-core conjugate vaccine

Beyond the preview

Go deeper on Shigella sonnei O-SP-core conjugate vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shigella sonnei O-SP-core conjugate vaccine.

Explore the full profile